Nanomedicine strategies for acute respiratory distress syndrome management
Source abstract
Abstract
Acute Respiratory Distress Syndrome (ARDS) remains a critical condition, characterized by severe respiratory failure and high mortality, despite significant advances in understanding its pathophysiology. Current treatments are largely supportive, with no definitive pharmacological solutions available. This review explores the potential of nanomedicine in ARDS management, focusing on nanocarrier-based delivery systems. Lipid nanoparticles (LNPs), particularly for RNA therapeutics, and nanostructured lipid carriers (NLCs) for conventional drug delivery, are highlighted for their enhanced targeting and stability profiles. The clinical success of LNPs in mRNA vaccine delivery demonstrates their efficacy in managing ARDS-related inflammation and tissue damage. Comparative analysis of various nanocarrier platforms reveals distinct advantages, with LNPs offering superior nucleic acid encapsulation efficiency, while NLCs provide enhanced drug-loading capacity and cost-effectiveness. Despite promising preclinical outcomes, clinical translation of nanomedicine in ARDS remains limited, constrained by challenges such as manufacturing scalability, regulatory hurdles, and potential immunogenicity. Moving forward, precision nanotherapies tailored to specific ARDS stages and triggers are essential for improving patient outcomes. This review underscores the need for further research to optimize nanocarrier properties and overcome current limitations, ultimately accelerating the clinical adoption of nanomedicine in ARDS treatment.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Lipid Membrane Structure and Behavior · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Zhejiang University Haining People’s Hospital, Haining Branch, The First Affiliated Hospital, , Haining,
Islamic Azad University Department of Fisheries, Science and Research Branch, , Tehran,
References (100+)
Show source-provided references
1. Acute respiratory distress syndrome10.1016/S0140-6736(21)00439-6 ↗
2. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries10.1001/jama.2016.0291 ↗
3. Acute respiratory distress syndrome10.1038/s41572-019-0069-0 ↗
4. Fifty years of research in ARDS. Is acute respiratory distress syndrome a preventable disease10.1164/rccm.201609-1767CI ↗
5. Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes10.1016/S0140-6736(22)01485-4 ↗
6. Acute respiratory distress syndrome: the Berlin definition10.1001/jama.2012.5669 ↗
7. Incidence and mortality of acute respiratory distress syndrome in children: a systematic review and meta-analysis10.1097/CCM.0000000000001388 ↗
8. Paediatric acute respiratory distress syndrome incidence and epidemiology (PARDIE): an international, observational study10.1016/S2213-2600(18)30344-8 ↗
9. Nanomedicine for the treatment of acute respiratory distress syndrome. The 2016 ATS bear cage award–winning proposal10.1513/AnnalsATS.201701-090PS ↗
10. Pulmonary drug delivery devices and nanosystems as potential treatment strategies for acute respiratory distress syndrome (ARDS)10.1016/j.ijpharm.2024.124182 ↗
11. Opportunities and challenges for inhalable nanomedicine formulations in respiratory diseases: a review10.2147/IJN.S446919 ↗
12. Comprehensive insights into mechanism of nanotoxicity, assessment methods and regulatory challenges of nanomedicines10.1186/s11671-024-04118-1 ↗
13. Solid lipid nanoparticles for targeted natural and synthetic drugs delivery in high-incidence cancers, and other diseases: roles of preparation methods, lipid composition, transitional stability, and release profiles in nanocarriers’ development10.1515/ntrev-2022-0517 ↗
14. Challenges in development of nanoparticle-based therapeutics10.1208/s12248-012-9339-4 ↗
15. Identification of early and intermediate biomarkers for ARDS mortality by multi-omic approaches10.1038/s41598-021-98053-1 ↗
16. Proteomic study of acute respiratory distress syndrome: current knowledge and implications for drug development10.1586/14789450.2016.1172481 ↗
17. Nanomedicine-based therapeutics to combat acute lung injury10.2147/IJN.S300594 ↗
18. Corticosteroids in ARDS
19. Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis10.1007/s00134-021-06394-2 ↗
20. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial10.1016/S2213-2600(19)30417-5 ↗
21. Early steroids and ventilator-associated pneumonia in COVID-19-related ARDS10.1186/s13054-022-04097-8 ↗
22. De Rubis · 2023
23. The effects of vitamin C on the multiple pathophysiological stages of COVID-1910.3390/life11121341 ↗
24. The effect of vitamin C on pathological parameters and survival duration of critically ill coronavirus disease 2019 patients: a randomized clinical trial10.3389/fimmu.2021.717816 ↗
25. Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial10.1016/j.ejphar.2020.173494 ↗
26. A novel combination of vitamin C, curcumin and glycyrrhizic acid potentially regulates immune and inflammatory response associated with coronavirus infections: a perspective from system biology analysis10.3390/nu12041193 ↗
27. Intravenous ascorbic acid and lung function in severely ill COVID-19 patients10.3390/metabo12090865 ↗
28. Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial10.1001/jama.2019.11825 ↗
29. Side effects of ruxolitinib in patients with SARS-CoV-2 infection: two case reports10.1016/j.ijantimicag.2020.106023 ↗
30. Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness10.1080/14740338.2021.1962284 ↗
31. Remdesivir: a potential game-changer or just a myth? A systematic review and meta-analysis10.1016/j.lfs.2020.118663 ↗
32. Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials10.1136/bmjopen-2020-048502 ↗
33. Anakinra for severe forms of COVID-19: a cohort study10.1016/S2665-9913(20)30164-8 ↗
34. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study10.1016/j.ijid.2020.11.149 ↗
35. Role of nebulized heparin in clinical outcome of COVID-19 patients with respiratory symptoms: a systematic review10.5005/jp-journals-10071-24511 ↗
36. Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial10.1016/S2213-2600(20)30470-7 ↗
37. Muthu · 2012 · 307
38. Drug delivery systems based on polymeric micelles and ultrasound: a review10.2174/1381612822666160217125215 ↗
39. Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics10.7150/thno.38069 ↗
40. Nanomedicine for acute respiratory distress syndrome: the latest application, targeting strategy, and rational design10.1016/j.apsb.2021.04.023 ↗
41. Biomedical application of reactive oxygen species–responsive nanocarriers in cancer, inflammation, and neurodegenerative diseases10.3389/fchem.2020.00838 ↗
42. Chemical basis of interactions between engineered nanoparticles and biological systems10.1021/cr400295a ↗
43. Charge-reversible nanoparticles: advanced delivery systems for therapy and diagnosis10.1002/smll.202304713 ↗
44. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration10.1016/j.biomaterials.2007.12.037 ↗
45. Brenner · 2020 · A450510.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A4505 ↗
46. Protein corona-enabled systemic delivery and targeting of nanoparticles10.1208/s12248-020-00464-x ↗
47. Recent advances in lipid nanoparticles and their safety concerns for mRNA delivery10.3390/vaccines12101148 ↗
48. Pathological mechanisms of liver injury caused by continuous intraperitoneal injection of silica nanoparticles10.1016/j.biomaterials.2011.12.008 ↗
49. Long-term respiratory exposure to amorphous silica nanoparticles promoted systemic inflammation and progression of fibrosis in a susceptible mouse model10.1016/j.chemosphere.2022.134633 ↗
50. Safety and toxicity implications of multifunctional drug delivery nanocarriers on reproductive systems in vitro and in vivo10.3389/ftox.2022.895667 ↗
51. Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy10.7150/thno.38425 ↗
52. Triggering immune system with nanomaterials for cancer immunotherapy10.3389/fbioe.2022.878524 ↗
53. Medical nanoparticles for next generation drug delivery to the lungs10.1183/09031936.00212813 ↗
54. Deposition of inhaled particles in the lungs10.1016/j.arbr.2012.02.006 ↗
55. Inflammation-modulating nanoparticles for pneumonia therapy10.1002/wnan.1763 ↗
56. Nanodelivery in airway diseases: challenges and therapeutic applications10.1016/j.nano.2009.07.001 ↗
57. Polystyrene nanoparticle trafficking across alveolar epithelium10.1016/j.nano.2008.02.002 ↗
58. Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery10.1016/j.drudis.2019.09.023 ↗
59. Physiological factors affecting lung deposition10.1089/jamp.2021.29036.csk ↗
60. Emerging application of nanomedicine-based therapy in acute respiratory distress syndrome10.1016/j.colsurfb.2024.113869 ↗
61. Macrophage-targeted nanomedicines for ARDS/ALI: promise and potential10.1007/s10753-022-01692-3 ↗
62. Nanotherapeutics in the treatment of acute respiratory distress syndrome10.1016/j.lfs.2021.119428 ↗
63. Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis10.1073/pnas.2116271119 ↗
64. Natural products-based inhaled formulations for treating pulmonary diseases10.2147/IJN.S451206 ↗
65. Resolving gene-environment interactions in complex traits: acute lung injury
66. Synthesis and characterization of pH-responsive PEG-poly (β-amino ester) block copolymer micelles as drug carriers to eliminate cancer stem cells10.3390/pharmaceutics12020111 ↗
67. The interplay of lung surfactant proteins and lipids assimilates the macrophage clearance of nanoparticles10.1371/journal.pone.0040775 ↗
68. Revealing the pulmonary surfactant corona on silica nanoparticles by cryo-transmission electron microscopy10.1039/c9na00779b ↗
69. Supramolecular arrangement of protein in nanoparticle structures predicts nanoparticle tropism for neutrophils in acute lung inflammation10.1038/s41565-021-00997-y ↗
70. Mechanistic insights into nanoparticle surface-bacterial membrane interactions in overcoming antibiotic resistance10.3389/fmicb.2023.1135579 ↗
71. Novel application of nanomedicine for the treatment of acute lung injury: a literature review10.1177/17534666241244974 ↗
72. Critical determinants of uptake and translocation of nanoparticles by the human pulmonary alveolar epithelium10.1021/nn505399e ↗
73. Nanotherapy therapy for acute respiratory distress syndrome: a review10.3389/fmed.2024.1492007 ↗
74. Mechanistic insights into sphingomyelin nanoemulsions as drug delivery systems for non-small cell lung cancer therapy
75. Mannose receptors of alveolar macrophages as a target for the addressed delivery of medicines to the lungs10.1134/S1068162022010150 ↗
76. A narrative review: the role of NETs in acute respiratory distress syndrome/acute lung injury10.3390/ijms25031464 ↗
77. Pulmonary drug delivery for acute respiratory distress syndrome10.1016/j.pupt.2023.102196 ↗
78. Membrane fusion biophysical analysis of fusogenic liposomes10.1021/acs.langmuir.2c01169 ↗
79. Lung targeted liposomes for treating ARDS10.1016/j.jconrel.2022.03.028 ↗
80. iRGD conjugated nimbolide liposomes protect against endotoxin induced acute respiratory distress syndrome10.1016/j.nano.2020.102351 ↗
81. Inhalation of L-arginine-modified liposomes targeting M1 macrophages to enhance curcumin therapeutic efficacy in ALI10.1016/j.ejpb.2022.11.017 ↗
82. Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections10.1016/j.jconrel.2007.12.011 ↗
83. Creation of lung-targeted dexamethasone immunoliposome and its therapeutic effect on bleomycin-induced lung injury in rats10.1371/journal.pone.0058275 ↗
84. Neutrophil membrane-coated therapeutic liposomes for targeted treatment in acute lung injury10.1016/j.ijpharm.2022.121971 ↗
85. Caveolar uptake and endothelial-protective effects of nanostructured lipid carriers in acid aspiration murine acute lung injury10.1007/s11095-013-1027-2 ↗
86. Layer-by-layer coated hybrid nanoparticles with pH-sensitivity for drug delivery to treat acute lung infection10.1080/10717544.2021.2000676 ↗
87. An inhalable hybrid biomimetic nanoplatform for sequential drug release and remodeling lung immune homeostasis in acute lung injury treatment10.1021/acsnano.3c02075 ↗
88. Lipid envelope-type nanoparticle incorporating a multifunctional peptide for systemic siRNA delivery to the pulmonary endothelium10.1021/nn401317t ↗
89. Intratracheally instilled mannosylated cationic liposome/NFkappaB decoy complexes for effective prevention of LPS-induced lung inflammation10.1016/j.jconrel.2009.12.016 ↗
90. Enhanced anti-inflammation of inhaled dexamethasone palmitate using mannosylated liposomes in an endotoxin-induced lung inflammation model10.1124/mol.108.050153 ↗
91. Macrophage-targeted lipid nanoparticle delivery of microRNA-146a to mitigate hemorrhagic shock-induced acute respiratory distress syndrome10.1021/acsnano.3c01814 ↗
92. Hybrid biomimetic nanovesicles to drive high lung biodistribution and prevent cytokine storm for ARDS treatment10.1021/acsnano.2c06357 ↗
93. Surfactant protein-A nanobody-conjugated liposomes loaded with methylprednisolone increase lung-targeting specificity and therapeutic effect for acute lung injury10.1080/10717544.2017.1402217 ↗
94. Anti-ICAM-1 antibody-modified nanostructured lipid carriers: a pulmonary vascular endothelium-targeted device for acute lung injury therapy10.1186/s12951-018-0431-5 ↗
95. Targeting delivery of simvastatin using ICAM-1 antibody-conjugated nanostructured lipid carriers for acute lung injury therapy10.1080/10717544.2016.1259369 ↗
96. Bioengineered neutrophil extinguisher targets Cascade immune pathways of macrophages for alleviating cytokine storm in pneumonia10.1021/acsnano.3c00227 ↗
97. Bioinspired DNase-I-coated melanin-like nanospheres for modulation of infection-associated NETosis dysregulation10.1002/advs.202001940 ↗
98. Erratum to targeting NOX4 alleviates sepsis-induced acute lung injury via attenuation of redox-sensitive activation of CaMKII/ERK1/2/MLCK and endothelial cell barrier dysfunction, redox biology 36 (2020) 10163810.1016/j.redox.2021.102200 ↗
99. Pathogenesis of acute respiratory distress syndrome10.1055/s-0039-1683996 ↗
100. Classic signaling pathways in alveolar injury and repair involved in sepsis-induced ALI/ARDS: new research progress and prospect10.1155/2022/6362344 ↗